Nazila Habibizad - Apr 1, 2022 Form 4 Insider Report for Global Blood Therapeutics, Inc. (GBT)

Role
Executive Vice President, Operations
Signature
/s/ Miguel Carrillo, Attorney-in-Fact
Stock symbol
GBT
Transactions as of
Apr 1, 2022
Transactions value $
-$19,391
Form type
4
Date filed
4/5/2022, 07:00 PM
Previous filing
Aug 3, 2022
Next filing
Aug 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Options Exercise +1.56K +5.37% 30.6K Apr 1, 2022 Direct F1
transaction GBT Common Stock Tax liability -$19.4K -540 -1.77% $35.91 30K Apr 1, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -1.38K -25% $0.00 4.13K Apr 1, 2022 Common Stock 1.38K Direct F1, F3
transaction GBT Restricted Stock Units Options Exercise $0 -183 -20.04% $0.00 730 Apr 1, 2022 Common Stock 183 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F2 Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,558 shares of Common Stock underlying the Reporting Person's RSUs.
F3 The shares of Common Stock underlying the RSUs vest in eight semi-annual installments from October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
F4 The shares of Common Stock underlying the RSUs vest in eight semi-annual installments from April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Executive Vice President, Operations